文献速递甲状腺疾病

低剂量放射性碘联合重组人促甲状腺激素消融后分化型甲状腺癌复发:HiLo长期结果

Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2018-11-27

HiLo是一项开放标签非劣效随机对照试验,纳入438例分化型甲状腺癌患者,比较1·1 GBq与3·7 GBq放射性碘消融的复发率。中位随访6·5年,两组累积复发率相似(7年5·9% vs 7·3%,HR 1·10,95%CI 0·47-2·59,p=0·83)。rhTSH与甲状腺激素撤药准备组的复发率也无显著差异。

要点

  • 低剂量1·1 GBq与高剂量3·7 GBq消融后7年累积复发率无显著差异。
  • 使用rhTSH准备与甲状腺激素撤药准备的复发风险相似。
  • 结果支持低危分化型甲状腺癌采用低剂量放射性碘消融。

核心结论

  • 1·1 GBq放射性碘消融后的复发率不高于3·7 GBq,支持低危分化型甲状腺癌使用低剂量放射性碘。
  • 复发风险不受使用rhTSH影响。

研究设计与样本

  • HiLo为在英国29个中心开展的非劣效、平行、开放标签、随机对照析因试验。
  • 纳入438例16-80岁经组织学确诊、需放射性碘消融的分化型甲状腺癌患者,随机分配至1·1 GBq或3·7 GBq消融,各采用rhTSH或甲状腺激素撤药准备。
  • 主要分析基于434例患者(低剂量组217例,高剂量组217例),中位随访6·5年(IQR 4·5-7·6)。

主要发现

  • 确认复发21例:1·1 GBq组11例,3·7 GBq组10例,其中4例(每组2例)视为持续性疾病。
  • 低剂量与高剂量组累积复发率相似:3年1·5% vs 2·1%,5年2·1% vs 2·7%,7年5·9% vs 7·3%;HR 1·10(95%CI 0·47-2·59),p=0·83。
  • T3或N1疾病未见风险显著差异。
  • rhTSH准备与甲状腺激素撤药准备组累积复发率相似:3年1·5% vs 2·1%,5年2·1% vs 2·7%,7年8·3% vs 5·0%;HR 1·62(95%CI 0·67-3·91),p=0·28。
  • 随访期间未收集不良事件数据。

关键数值与推荐

  • 低剂量放射性碘剂量为1·1 GBq,高剂量为3·7 GBq。
  • 非劣效设计比较复发率,主要终点为至首次复发时间,为预先设定的次要结局。

临床怎么用

  • 对于低危分化型甲状腺癌患者,可考虑使用1·1 GBq低剂量放射性碘进行消融。
  • 消融前准备可选择rhTSH,不增加复发风险。

局限性

  • 随访期间未收集不良事件数据。
  • 复发诊断基于各医院常规方法,未集中判读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Two large randomised trials of patients with well-differentiated thyroid cancer reported in 2012 (HiLo and ESTIMABL1) found similar post-ablation success rates at 6-9 months between a low administered radioactive iodine (131I) dose (1·1 GBq) and the standard high dose (3·7 GBq). However, recurrence rates following radioactive iodine ablation have previously only been reported in observational studies, and recently in ESTIMABL1. We aimed to compare recurrence rates between radioactive iodine doses in HiLo. METHODS: HiLo was a non-inferiority, parallel, open-label, randomised controlled factorial trial done at 29 centres in the UK. Eligible patients were aged 16-80 years with histological confirmation of differentiated thyroid cancer requiring radioactive iodine ablation (performance status 0-2, tumour stage T1-T3 with the possibility of lymph-node involvement but no distant metastasis and no microscopic residual disease, and one-stage or two-stage total thyroidectomy). Patients were randomly assigned (1:1:1:1) to 1·1 GBq or 3·7 GBq ablation, each prepared with either recombinant human thyroid-stimulating hormone (rhTSH) or thyroid hormone withdrawal. Patients were followed up at annual clinic visits. Recurrences were diagnosed at each hospital with a combination of established methods according to national standards. We used Kaplan-Meier curves and hazard ratios (HRs) for time to first recurrence, which was a pre-planned secondary outcome. This trial is registered with ClinicalTrials.gov, number NCT00415233. RESULTS: Between Jan 16, 2007, and July 1, 2010, 438 patients were randomly assigned. At the end of the follow-up period in Dec 31, 2017, median follow-up was 6·5 years (IQR 4·5-7·6) in 434 patients (217 in the low-dose group and 217 in the high-dose group). Confirmed recurrences were seen in 21 patients: 11 who had 1·1 GBq ablation and ten who had 3·7 GBq ablation. Four of these (two in each group) were considered to be persistent disease. Cumulative recurrence rates were similar between low-dose and high-dose radioactive iodine groups (3 years, 1·5% vs 2·1%; 5 years, 2·1% vs 2·7%; and 7 years, 5·9% vs 7·3%; HR 1·10 [95% CI 0·47-2·59]; p=0·83). No material difference in risk was seen for T3 or N1 disease. Recurrence rates were also similar among patients who were prepared for ablation with rhTSH and those prepared with thyroid hormone withdrawal (3 years, 1·5% vs 2·1%; 5 years, 2·1% vs 2·7%; and 7 years, 8·3% vs 5·0%; HR 1·62 [95% CI 0·67-3·91]; p=0·28). Data on adverse events were not collected during follow-up. INTERPRETATION: The recurrence rate among patients who had 1·1 GBq radioactive iodine ablation was not higher than that for 3·7 GBq, consistent with data from large, recent observational studies. These findings provide further evidence in favour of using low-dose radioactive iodine for treatment of patients with low-risk differentiated thyroid cancer. Our data also indicate that recurrence risk was not affected by use of rhTSH. FUNDING: Cancer Research UK.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Dehbi HM, Mallick U, Wadsley J, et al. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol. 2018. PMID: 30501974. doi:10.1016/S2213-8587(18)30306-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。